

**THE ASSOCIATION OF HLA CLASS II
DR ALLELES WITH THE OUTCOME
OF HCV INFECTION
IN EGYPTIAN CHILDREN AND
ADOLESCENTS**

Thesis

Submitted for partial fulfillment of MD degree in
Tropical Medicine

By

Mona Abdel Fattah Ghoneim

(M.B.,B.Ch-Msc)

Cairo University

Supervised By

Prof.Dr. Ayman Yosry

Professor of Tropical Medicine

Cairo University

Prof.Dr. Rabab Fouad

Professor of Tropical Medicine

Cairo University

Prof.Dr. Shereen Mahmoud

Professor of Clinical Pathology

Cairo University


Prof.Dr. Mona El-Raziky

Assist. Professor of Pediatrics

Cairo University

Cairo University – Faculty of Medicine

2009



Acknowledgemnt

***"First and Foremost, Thanks are due to GOD,
The Beneficent and Merciful of ALL"***

*I would like to express my deepest gratitude and sincere thanks to **Prof, Dr. Ayman Yosry**, Professor of Tropical Medicine, Faculty of Medicine , Cairo University for his continuous guidance , invaluable instructions , indispensable advice throughout the work. I have been greatly honored to work under his supervision.*

*My deepest gratitude to **Prof, Dr. Rabab Fouad** , Professor of Tropical Medicine, Faculty of Medicine , Cairo University for her generous supervision, expert guidance , careful reading, valuable and unfailing instructions and unlimited encouragement throughout the whole work. She has generously devoted much of her time and effort for planning and supervision of this work.*

*I am greatly indebted to **Prof, Dr. Shereen Mahmoud** , Professor of Clinical Pathology, Faculty of Medicine , Cairo University for her support , advice , guidance and tremendous efforts in processing , reading and offering all facilities for the laboratory work.*

*No words can express my sincere feelings and deep respect to **Prof, Dr. Mona El Raziky**, Professor of Pediatrics, Faculty of Medicine, Cairo University for devoting her intellectual energies and high sense of profession in the entire development of this thesis. Without her creative thinking, valuable suggestions and constructive criticism, the performance of this work would have been much more difficult. I have learned a great deal and gained valuable experience.*

*My deepest gratitude to **Prof, Dr. Mahasen Abdel-Rahman**, Head of Tropical Medicine Department, Cairo University, for her kindness , support and giving chances for better learning.*

*I also appreciate the role of the Bilharzial Liver Unit headed by **Prof, Dr. Gamal Esmat** , Professor of Tropical Medicine, Faculty of Medicine , Cairo University who offered all facilities needed for this work.*

*In addition, I want to express my extreme thankfulness to **Prof, Dr. Hanaa El- Karaksy**, professor of Pediatrics, Faculty of Medicine, Cairo University for her precious help and effort.*

*My particular sincere thanks to **Prof, Dr. Mohammed Salah Abd El Bary**, Assistant Professor of Tropical Medicine, Faculty of Medicine , Cairo University for generous help, guidance, kind encouragement and great fruitful advice throughout this work.*

Finally, I would like to express my gratefulness for my beloved family for their extended patience and moral support.

TABLE OF CONTENTS

	<i>Page</i>
--Abstract	<i>I</i>
--Introduction and aim of the work	<i>III</i>
I.EPIDEMIOLOGY OF HCV	<i>1</i>
• <i>Prevalence</i>	<i>1</i>
• <i>Methods of transmission</i>	<i>6</i>
• <i>Epidemiology in Egypt</i>	<i>11</i>
• <i>Epidimology in children</i>	<i>17</i>
II. HCV VIRUS	<i>24</i>
• <i>HCV genotypes, subtypes and quasispecies</i>	<i>24</i>
• <i>The biological relevance of quasispecies</i>	<i>31</i>
• <i>Viral fitness and quasispecies</i>	<i>32</i>
• <i>Immune escape as a mechanism for viral persistence</i>	<i>34</i>
• <i>Humoral immunity</i>	<i>35</i>
• <i>Cellular immunity</i>	<i>37</i>
III. DIAGNOSIS OF HCV	<i>40</i>
IV. The Human Leukocyte Antigen (HLA) System	<i>45</i>
• <i>The HLA Antigens</i>	<i>47</i>
• <i>Genetics Of HLA</i>	<i>57</i>
• <i>Methods Of Testing For HLA Antigens</i>	<i>60</i>
• <i>Clinical Relevance Of The HLA System</i>	<i>64</i>
• <i>HLA And Disease</i>	<i>68</i>
• <i>HLA class II diversity and disease susceptibility</i>	<i>69</i>
V.HLA Allele Associations With Hepatitis C Infection In Global Populations	<i>81</i>
• <i>HLA and natural history of HCV</i>	<i>81</i>
• <i>HLA associations with clearance of HCV infection</i>	<i>83</i>
• <i>HLA associations with susceptibility to infection and progression</i>	<i>87</i>
• <i>HLA associations with the extra-hepatic manifestations of hepatitis C viral infections</i>	<i>90</i>
• <i>HLA associations with vertical transmission of hepatitis C viral infections</i>	<i>91</i>
• <i>HLA allele associations with response to interferon therapy in hepatitis C viral infections</i>	<i>92</i>
--Materials and Methods	<i>101</i>
--Results	<i>114</i>
--Discussion	<i>140</i>
--Summary and conclusion	<i>153</i>
--Recommendations	<i>156</i>
--References	<i>157</i>
--Arabic Summary	<i>194</i>

List of Tables

No	Title	Page
<i>I</i>	<i>Hepatitis C estimated prevalence and number infected</i>	<i>2</i>
<i>II</i>	<i>Possible risk factors for vertical transmission which have been investigated to a varying degree</i>	<i>19</i>
<i>III</i>	<i>HLA association with TB</i>	<i>75</i>
<i>IV</i>	<i>HLA association with leprosy</i>	<i>76</i>
<i>V</i>	<i>HLA association with HIV I disease progression to Aids</i>	<i>77</i>
<i>VI</i>	<i>Association of HLA alleles with chronic HBV infection across global populations</i>	<i>79</i>
<i>VII</i>	<i>Association of HLA alleles with protection from HCV infection and viral clearance</i>	<i>84</i>
<i>VIII</i>	<i>Association of HLA alleles with susceptibility to viral persistence and chronic HCV infection across global populations</i>	<i>87</i>
<i>IX</i>	<i>Association of HLA alleles with response to interferon in chronic hepatitis</i>	<i>97</i>
<i>1</i>	<i>Demographic data of the studied children</i>	<i>114</i>
<i>2</i>	<i>Risk factors of the studied children</i>	<i>115</i>
<i>3a</i>	<i>Cumulative risk factors in both groups</i>	<i>116</i>
<i>3b</i>	<i>Cumulative risk factors in both groups</i>	<i>116</i>
<i>4</i>	<i>Co- morbid conditions in chronic HCV patients</i>	<i>117</i>
<i>5</i>	<i>Clinical presentations of studied patients</i>	<i>117</i>
<i>6</i>	<i>Abdominal ultrasonographic finding of the studied patients</i>	<i>118</i>
<i>7</i>	<i>The blood counts & liver biochemical profile of the studied groups</i>	<i>118</i>
<i>8</i>	<i>Frequency of normal & abnormal ALT levels among the patients</i>	<i>119</i>
<i>9a</i>	<i>Histological Activity index in the studied patients</i>	<i>119</i>
<i>9b</i>	<i>Fibrosis stage in the studied patients</i>	<i>119</i>
<i>9c</i>	<i>Relation between HAI and Fibrosis stage</i>	<i>120</i>
<i>10a</i>	<i>Relation between ALT level and the grade of inflammation</i>	<i>121</i>
<i>10b</i>	<i>Relation between ALT level and the grade of inflammation</i>	<i>122</i>
<i>11a</i>	<i>Relation between ALT level and fibrosis score</i>	<i>122</i>
<i>11b</i>	<i>Relation between ALT level and fibrosis score</i>	<i>123</i>
<i>12</i>	<i>Relation between number of risk factors and the grade of inflammation</i>	<i>123</i>
<i>13</i>	<i>Relation between number of risk factors and fibrosis stage</i>	<i>123</i>
<i>14</i>	<i>Relation between co-morbid condition and grade of inflammation</i>	<i>124</i>
<i>15</i>	<i>Relation between co-morbid condition and grade of inflammation</i>	<i>124</i>
<i>16</i>	<i>HLA DRB Alleles frequency among the 46 studied chronic infected HCV patients.</i>	<i>126</i>
<i>17</i>	<i>HLA DRB Alleles frequency among the 20 control subjects versus 46 HCV patients</i>	<i>126</i>

18a	<i>HLA DRB Alleles frequency compared with serum ALT levels</i>	127
18b	<i>HLA DRB Alleles frequency compared with serum ALT levels</i>	128
19	<i>HLA DRB1 Alleles frequency compared with Histological Activity Index</i>	129
20	<i>Fibrosis stages in the studied patients in relation to HLA genotypes</i>	130
21	<i>Demographic data of the studied patients in relation to the allele HLA DRB1*03</i>	131
22	<i>Risk factors of the 46 HCV patients studied groups in relation to HLA DRB1*03</i>	132
23	<i>Clinical features of the studied patients in relation to HLA DRB1*03</i>	132
24	<i>Abdominal Ultrasonographic finding of patients and HLA DRB1*03</i>	132
25	<i>Laboratory profile of patients in relation to HLA DRB1*03</i>	133
26	<i>Demographic characteristic of the studied patients in relation to HLA DRB1*04</i>	134
27	<i>Risk factors in the studied patients in relation to HLA DRB1*04</i>	134
28	<i>Clinical symptoms and signs in patients in relation to HLA DRB1*04</i>	135
29	<i>Abdominal ultrasonographic findings in the studied patients in relation to HLA DRB1*04</i>	135
30	<i>Laboratory profile of the studied patients and HLA DRB1*04</i>	136
31	<i>Demographic characteristic of the studied patients in relation to HLA DRB1*13</i>	137
32	<i>Risk factors in the studied patients in relation to HLA DRB1*13</i>	137
33	<i>Clinical symptoms and signs in the studied patients in relation to HLA DRB1*13</i>	138
34	<i>Abdominal ultrasonographic findings and HLA DRB1*13</i>	138
35	<i>Laboratory profile and HLA DRB1*13</i>	138

List of Figures

No	Title	Page
I.	<i>Estimated HCV prevalence by regions</i>	3
II.	<i>Age specific prevalence of antibody to hepatitis C virus by selected countries</i>	12
III.	<i>Proportion with HCV antibodies among 10-50 years by geographical area</i>	12
IV.	<i>HCV model structure and genome organization</i>	25
V.	<i>Worldwide geographical distribution of genotypes</i>	28
VI.	<i>Schematic representation of the quasispecies evolution of virus after infection of different hosts</i>	33
VII.	<i>Humoral immune response to viral envelope proteins</i>	36
VIII.	<i>Location and organization of HLA complex</i>	45
IX.	<i>HLA gene complex</i>	47
X.	<i>Structure of MHC class I and II molecule</i>	48
XI.	<i>Structure of class I and II molecule</i>	50
XII.	<i>Antigen processing</i>	54
XIII.	<i>Interaction between T – cell receptors and HLA peptide complex</i>	55
XIV.	<i>SSOP hydridised band</i>	63
1	<i>Risk factors of the studied children</i>	115
2	<i>Cumulative risk factors in both groups</i>	116
3	<i>Relation between HAI and Fibrosis stage</i>	120
4	<i>HLA DRB1 frequency among studied patients</i>	125
5	<i>HLA DRB1 frequency among the studied 46 patients</i>	131
6	<i>Comparison of platelets count in relation to DRB1*03</i>	133
7	<i>Comparison of serum albumin in relation to DRB1*04</i>	136
8	<i>Comparison of AST levels in relation to DRB1*13</i>	139

List of abbreviations

AASLD	American association of the study of liver diseases
Ab	Antibody
AC	Asymptomatic carriers
AFP	Alfa feotoprotein
AIH	Autoimmune Hepatitis
ALT	Alanine aminotransferase
APC	Antigen presenting cell
Arg	Arginine
ATL	Adult T cell Leukemia
BMT	Bone marrow transplantation
CD	Celiac Disease
CD	Cluster of differentiation
CD4+	Helper T cells
CD8+	Cytotoxic T cells
CHC	Chronic hepatitis C
CLD	Chronic liver disease
CTLs	Cytolytic T lymphocytes
CVID	Common variable immunodeficiency disease
DCs	Dendritic cell
E	Envelope
EIA	Immunosorbant assay
ETR	End treatment response
FMDV	Foot and mouth disease virus
GVHD	Graft versus host disease
HA	Hyaluronic acid
HAART	Highly active antiretroviral therapy
HAM	Human cell Leukemia virus 1- associated myelopathy
HAV	Hepatitis A Virus
HBV	Hepatitis B Virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C Virus
HEV	Hepatitis E Virus
HIV	Human Immune Deficiency Virus
HLA	Human leucocyte Antigen
HSCT	Haematopoietic stem cell transplantation
HVR	Hypervariable region
IDDM	Insulin Dependent Diabetes Mellitus
IDUS	Injecting drug users
IFN	Interferon
IG	Immunoglobulin
IgM	Immunoglobulin M
IM	Intramuscular
IV	Intravenous
JCA	Juvenile chronic arthritis
Kd	Kilo Dalton
LC	Liver cirrhosis
LDALT	Living donor adult liver transplantation
LRLT	Liver related liver transplantation

Lys	Lysine
MHC	Major Histocompatibility Complex
MLC	Mixed lymphocyte culture
MS	Multiple Sclerosis
NC	Normal control
NHANES	National Health and Nutrition Examination and Survey
NS	Non structural
Peg	Pegylated
R	Recovered
RA	Rheumatoid Arthritis
RFLP	Restriction Fragments Length Polymorphism
RIBA	Recombinant immunoblot assay
RNA	Ribonucleic acid
SLE	Systemic Lupus Erythematosus
SSO	Sequence Specific Oligonucleotide Typing
SSP	Sequence Specific Priming
SVR	Sustained viral response
T1D	Type 1 Diabetes
TAP	Transporters associated with processing
TB	Tuberculosis
TCR	T cell receptor
US	United States of America
UTR	Untranslated regions
VP	Viral persistence
VSV	Vesicular Stomatitis virus
WHO	World Health Organization

Abstract

Hepatitis C virus (HCV) infection is a global medical problem. The immune response to HCV is an important determinant of disease evolution and can be influenced by various host factors. HLA class II may play an important role in immune response against HCV. The association between HLA class II antigen and HCV in different ethnic populations that has been reported is controversial. Therefore the objective of the present study was to determine the distribution of HLA class II DRB1 alleles, to confirm the influence of these antigens on the outcome of HCV infection and to assess the relationship between these antigens with clinical , laboratory and histological state of the liver among Egyptian children and adolescents with chronic HCV infection . Methods: HLA class II DNA typing was performed by means of Hybridization with sequence specific oligonucleotide probes, after amplification of the second exon of the DRB1 genes using the RELI TM SSO HLA- DRB typing test. Forty six Egyptian patients with chronic HCV infection were included in the study (29 males and 17 females) with age range 3-17 years (10.4 years (y) \pm 4.232); and 20 normal healthy control subjects. Results: HLA DRB1*15 was found significantly with reduced frequency among our cases when compared with controls (8.7%vs 45%) $P<0.01$. There were higher frequencies of HLA-DRB1*03, DRB1*04 and DRB1*13 in patients compared with controls (45.6, 39.1 and 26.1%) respectively, indicating a possible implication of these alleles with chronic HCV infection. There was no significant correlation upon comparing the frequency of these alleles with demographic characteristics, risk factors of HCV acquisition, co-morbid condition, clinical presentation, abdominal ultrasonographic picture, biochemical profile and histopathological examination in our patients.

However; patients possessing the allele DRB1*03 were encountered with significant reduced platelet count $p=0.03$ and this allele was presented with high frequency in patients with minimal grade of inflammation but it did not reach a statistical significance $p=0.06$, though it was very close. Patients with DRB1*04 had significantly low serum albumin $p=0.04$ and patients with DRB1*13 had a significant high serum AST levels $p=0.05$. These findings agree with the association of these alleles and the development of chronic HCV infection.

Therefore, it can be concluded that the allele DRB1*15 is associated with protection from chronic HCV infection and the alleles DRB1*03-*04 -*13 could be associated with chronic HCV infection in Egyptian patients; However larger group of patients is needed for statistical values to be more significant.

Key words: Children; Egypt; HLA class II; Hepatitis C virus; Liver

INTRODUCTION AND AIM OF THE WORK

Hepatitis C virus infection is an increasingly major health problem, threat and concern world wide. There are 170 million infected individuals world wide, i.e., the prevalence of infection is nearly 3% (**Schafer, et al 2004**).

Egypt has higher rates of HCV than neighboring countries as well as other countries in the world with comparable socioeconomic conditions and hygienic standards for invasive medical, dental, or paramedical procedures (**Zakaria, et al 2005**).

Chronic hepatitis C varies greatly in its course and outcome. At one end of the spectrum are patients who have no signs or symptoms of liver disease and completely normal levels of serum liver enzymes. Liver biopsy usually shows some degree of chronic hepatitis, but the degree of injury is usually mild, and the overall prognosis may be good. At the other end of the spectrum are patients with severe hepatitis C who have symptoms, HCV RNA in serum, and elevated serum liver enzymes, and who ultimately develop cirrhosis and end-stage liver disease. In the middle of the spectrum are many patients who have few or no symptoms, mild to moderate elevations in liver enzymes, and an uncertain prognosis

(Alter & Seeff, 2000).

HCV in pediatric patients is in general terms a slow progressive disease, but a number of patients have a more aggressive course leading to early cirrhosis. Therefore, children with chronic HCV need to have early evaluation, consistent follow-up and despite repeated normal or mildly abnormal transaminases, it is advisable to obtain baseline liver histology with potential follow-up

biopsies in 5-10 yr to tailor timing for treatment (**Rumbo, 2005**).

The class I and class II human leukocyte antigens (HLA) are central to the host immune response and thus are ideal candidate genes to investigate for associations with HCV outcomes. Class I and class II HLA are encoded by the most polymorphic genes known and present antigen to CD8+ cytotoxic T cells and CD4+ helper T cells, respectively. Polymorphisms in the peptide binding regions of these molecules determine antigenic specificities and the strength of the immune response to a given pathogen. Certain HLA alleles have been shown to influence the outcome of other chronic viral infections (**Thio et al, 2002**).

HLA class II antigen appears crucial for resolution or progression of HCV patients. The punctual identification of those genetic factors may, therefore, prove to be useful in predicting disease evolution, in guiding the appropriate therapy for patients with poor prognosis, and in encouraging the development of new therapeutic strategies (**Scotto et al, 2003**).

Patients with chronic hepatitis C and normal ALT levels have less severe liver disease than those with elevated ALT levels. This particular biochemical outcome may be explained, at least in part, by host immunogenetic factors such as presence of HLA DRB1*11(**Renou. et al, 2002**).

In a Chinese study the association between HCV genotypes, HLA DRB alleles and patients response to IFN-alpha and ribavirin therapy displayed complete response to treatment with HLA DRB1*07 and HLA DRB1*04 demonstrated no response, which proves that it

is necessary to adjust the host's immune status to accelerate the clearance of HCV(**Jiao & Wang, 2005**).

Another Study done on Egyptian haemophilic children and adults showed that certain HLA DR alleles as DRB1*0101 and DRB1*0301 may have a role in HCV clearance and persistence (**Hamed et al, 2003**).

Extensive allele diversity is observed in HLA associations with susceptibility and protection regarding HCV infection and disease progression in different global ethnic populations (**Singh et al, 2007**).

AIM OF THE WORK

The aim of this study is to asses the relationship between HLA class II antigens with the clinical, laboratory and histopathological state of the liver among Egyptian children and adolescents with chronic HCV infection.